BPC-157 + GHK-Cu Hair Growth Research Stack

Hair follicle cycling is a tightly regulated biological process governed by the interplay of vascular supply, extracellular matrix remodelling, and dermal-papilla signalling. Disruptions in follicular angiogenesis — particularly the reduction in perifollicular capillary density that accompanies miniaturisation in androgenetic alopecia — are a well-established finding in the hair-biology literature. Two peptide research compounds, BPC-157 and GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), have attracted independent research interest for mechanisms directly relevant to the follicular microenvironment: BPC-157 for its documented up-regulation of vascular endothelial growth factor receptor 2 (VEGFR2) and its downstream angiogenic programme, and GHK-Cu — first described by biochemist Loren Pickart in the 1970s — for its capacity to stimulate dermal-papilla cell proliferation and extracellular matrix enzyme activation. This page summarises the preclinical evidence base for both compounds in the follicular context.

Why pair BPC-157 with GHK-Cu?

The scientific rationale for combining these two peptides rests on their anatomically and mechanistically complementary sites of action within the hair follicle unit. BPC-157, administered systemically, acts on the perifollicular vascular bed — the network of capillary loops that supplies the dermal papilla with oxygen and paracrine growth factors. Its VEGFR2-mediated angiogenic signal reaches the scalp via the circulation, meaning a single subcutaneous injection can influence follicular vascularisation across the entire scalp simultaneously. GHK-Cu, by contrast, acts most powerfully at the local tissue level: the copper ion serves as an essential cofactor for lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibres within the dermal-papilla matrix, while the tripeptide backbone directly stimulates dermal-papilla cell proliferation in culture models. Topical delivery concentrates the compound at the perifollicular dermis, achieving local concentrations that systemic delivery cannot replicate. The combination therefore operates along two independent and additive axes: systemic vascular support from BPC-157 and local matrix remodelling from GHK-Cu.

Mechanism of action — each peptide

Summarised studies on the combination

No registered clinical trial has examined the BPC-157 + GHK-Cu combination specifically in a hair-loss model. The research rationale for combining these compounds rests on convergent findings from independent preclinical programmes, each of which addressed one arm of the proposed mechanism.

The most directly relevant published study is that of Pyo et al. (2007, PMID 17225455), who examined the effect of the tripeptide-copper complex (the GHK-Cu moiety) on human hair growth in vitro. Using isolated hair follicles and dermal-papilla cell cultures, the researchers found that GHK-Cu promoted follicle elongation and dermal-papilla cell proliferation in a concentration-dependent manner. At the highest tested concentration, GHK-Cu produced follicle growth comparable in magnitude to minoxidil at 1 µM — the reference comparator drawn from the earlier primate work by Uno et al. (1987, PMID 2440783) that established minoxidil's efficacy in the bald stump-tailed macaque model. The Pyo study also identified up-regulation of vascular endothelial growth factor (VEGF) secretion from dermal-papilla cells treated with GHK-Cu, a finding that creates a molecular link between GHK-Cu's direct papilla effect and the follicular angiogenic programme that BPC-157 acts upon through VEGFR2.

The angiogenic arm of the proposed stack mechanism rests on Hsieh et al. (2017, PMID 28197666), who characterised the VEGFR2 dependence of BPC-157's pro-angiogenic signal in endothelial-cell culture and an in vivo Matrigel plug model. Perifollicular angiogenesis — the density and organisation of the capillary loop that feeds each follicle — is now well established as a rate-limiting factor in anagen initiation and maintenance, rather than a passive consequence of follicular activity. BPC-157's capacity to increase VEGFR2 expression and amplify endothelial responses to local VEGF gradients (including the VEGF secreted by dermal-papilla cells in response to GHK-Cu, per Pyo) represents a plausible systemic complement to GHK-Cu's local signal.

Pickart and Margolina (2018, PMID 30081441) further contextualised GHK-Cu's relevance to follicular biology by demonstrating its up-regulation of decorin — a proteoglycan that organises the collagen fibrillar architecture of the dermal papilla and suppresses TGF-β1-mediated follicular miniaturisation signalling. The combination of matrix stabilisation and suppression of miniaturisation signalling provides an additional rationale for GHK-Cu's presence in this stack beyond its direct proliferative effect on dermal-papilla cells.

All published data remain preclinical. No human-subject efficacy data exist for this specific combination.

Full research protocol

The protocol below reflects the dosing parameters most commonly cited in the published GHK-Cu dermal and BPC-157 angiogenesis literature, adapted to an 8-week research cycle.

Weekly research timeline

• Induction phase (weeks 1–2): BPC-157 commences at full dose; GHK-Cu begins at a lower topical concentration to assess local tolerability before escalating. The angiogenic signal from BPC-157 is established during this window.
• Full-dose phase (weeks 3–8): Both peptides run at their target research concentrations for the remainder of the cycle. GHK-Cu topical dose is maintained at 2 mg/day. Post-cycle observation of follicular response in animal models has been documented for 4–6 weeks after cessation.

Reconstitution & storage notes (research handling)

BPC-157 is typically reconstituted in bacteriostatic water at a concentration of 1 mg/mL (1,000 µg/mL), yielding a 500 µg dose per 0.5 mL injection. The reconstituted solution should be stored at 2–8 °C and is stable for approximately 30 days under refrigeration. Avoid repeated freeze-thaw cycles; aliquot into single-use vials before freezing for long-term storage. BPC-157 is administered via subcutaneous injection for systemic follicular vascular effects; the injection site need not be the scalp.

GHK-Cu for topical application is most commonly formulated at 1–5% in an appropriate carrier (propylene glycol, DMSO, or a liposomal vehicle) to facilitate percutaneous penetration to the perifollicular dermis. GHK-Cu powder reconstituted in aqueous solution is light-sensitive and should be stored in amber vials at 2–8 °C. If subcutaneous delivery of GHK-Cu is preferred for research purposes, 1 mg/mL in bacteriostatic water is the standard research concentration. Avoid prolonged exposure to air: the cupric ion can be reduced to Cu⁺ under oxidising conditions, and the resulting chemistry may degrade the peptide-copper complex.

Related research

For researchers exploring broader tissue-repair and skin-biology applications of these compounds, the following stacks extend the evidence base:

• BPC-157 + TB-500 Healing Stack — The most extensively documented two-peptide repair combination, pairing BPC-157's VEGFR2 angiogenesis with TB-500's progenitor-cell recruitment across tendon, ligament and cardiac models.
• GHK-Cu + TB-500 Skin Stack — Combines GHK-Cu's copper-dependent matrix remodelling with TB-500's actin-cytoskeletal and macrophage-polarisation mechanisms for dermal regeneration research.
• BPC-157 + TB-500 + GHK-Cu Advanced Recovery — Triple-peptide protocol adding copper-peptide matrix support to the established BPC-157/TB-500 angiogenic and progenitor-recruitment backbone.

For per-peptide mechanistic monographs, see PeptideAuthority.co.uk/peptides/bpc-157 and PeptideAuthority.co.uk/peptides/ghk-cu.